Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Inovio Pharma (INO) Misses Q2 EPS by 3c
August 8, 2019 5:53 PM EDTInovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.30), $0.03 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $135.67 thousand versus the consensus estimate of $5.66 million.
Dr. J. Joseph Kim, Inovio's President & CEO said, "Inovio is well-positioned to advance its... More
